P240028/S006: WiSE (Wireless Stimulation of the Endocardium Technology) CRT System
FDA’s recorded scope: qualification of a new supplier for the IrOx coating process on the needle tip of the WiSE CRT System
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 4 FDA records to the applicant name EBR Systems, Inc.. 1 entry is a PMA supplement. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 3, 2025 to Mar 27, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code SEG appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P240028, with 4 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 480 Oakmead Pkwy., Sunnyvale, CA, 94085. Recorded on P240028/S006, decision dated Mar 27, 2026.
Leadless Cardiac Resynchronization Therapy (CRT).
FDA’s recorded scope: qualification of a new supplier for the IrOx coating process on the needle tip of the WiSE CRT System
FDA’s recorded scope: to update manufacturing lot release testing requirements for M1000 and M2000 catheters.
FDA’s recorded scope: approval for an additional energy calibration inspection for the Transmitter subassembly
FDA’s recorded scope: additional wire bonder equipment
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.